Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Jeff H. Lipton
Observed names:
Jeff H Lipton,
Jeff Lipton,
Jeff H. Lipton,
Lipton, Jeff H.
Institution:
Princess Margaret Cancer Centre
Observed institutions:
Mount Sinai Hospital,
University Health Network,
University of Toronto,
Hospital for Sick Children,
Princess Margaret Cancer Centre,
Royal Manchester Children's Hospital,
Cell Therapy Transplant Canada,
Canadian Blood Services,
McMaster University
show all 9
OpenAlex ID:
A5110181966
Hematopoietic Stem Cell Transplantation A Global Perspective
2010
·
Alois Gratwohl
, Helen Baldomero
, et al.
·
JAMA
·
785
One million haemopoietic stem-cell transplants: a retrospective observational study
2015
·
Alois Gratwohl
, Marcelo C Pasquini
, et al.
·
The Lancet Haematology
·
510
A randomized controlled trial comparing the frequency of acute reactions to plasma‐removed platelets and prestorage WBC‐reduced platelets
2002
·
Nancy M. Heddle
, Morris A. Blajchman
, et al.
·
Transfusion
·
218
A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia
2012
·
Jerald P. Radich
, Kenneth J. Kopecky
, et al.
·
Blood
·
183
PDF
Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation
2012
·
Jorge Cortes
, Jeff H. Lipton
, et al.
·
Blood
·
145
Long‐term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib
2016
·
Jorge E. Cortes
, Hanna J. Khoury
, et al.
·
American Journal of Hematology
·
113
PDF
Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia
2014
·
Carlo Gambacorti‐Passerini
, Jorge E. Cortes
, et al.
·
American Journal of Hematology
·
112
PDF
Heterogeneity of chronic graft-versus-host disease biomarkers: association with CXCL10 and CXCR3+ NK cells
2016
·
Amina Kariminia
, Shernan G. Holtan
, et al.
·
Blood
·
104
Improving diagnostic precision, care and syndrome definitions using comprehensive next-generation sequencing for the inherited bone marrow failure syndromes
2015
·
Ibrahim Ghemlas
, Hongbing Li
, et al.
·
Journal of Medical Genetics
·
101
PDF
Long‐term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome‐positive leukemias treated with bosutinib
2016
·
Jorge E. Cortes
, H. Jean Khoury
, et al.
·
American Journal of Hematology
·
98
PDF
Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II study
2018
·
Carlo Gambacorti-Passerini
, Jorge E. Cortes
, et al.
·
Haematologica
·
71
PDF
An evaluation of the donor experience in the canadian multicenter randomized trial of bone marrow versus peripheral blood allografting
2004
·
Christopher Bredeson
, Chantal Leger
, et al.
·
Transplantation and Cellular Therapy
·
65
Effects of Bosutinib Treatment on Renal Function in Patients With Philadelphia Chromosome-Positive Leukemias
2017
·
Jorge E. Cortes
, Carlo Gambacorti-Passerini
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
·
58
PDF
Early hematopoietic reconstitution after clinical stem cell transplantation: evidence for stochastic stem cell behavior and limited acceleration in telomere loss
2002
·
Ian Thornley
, Robert Sutherland
, et al.
·
Blood
·
54
PDF
Factors influencing long‐term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib
2015
·
Tim H. Brümmendorf
, Jorge E. Cortes
, et al.
·
British Journal of Haematology
·
44
PDF
Illness intrusiveness among survivors of autologous blood and marrow transplantation
2001
·
Aaron D. Schimmer
, Mary E. Elliott
, et al.
·
Cancer
·
40
PDF
T-Cell Large Granular Lymphocytic Leukemia of Donor Origin Occurring After Allogeneic Bone Marrow Transplantation for B-Cell Lymphoproliferative Disorders
2005
·
Hong Chang
, Suzanne Kamel-Reid
, et al.
·
American Journal of Clinical Pathology
·
35
CD56 bright natural killer regulatory cells in filgrastim primed donor blood or marrow products regulate chronic graft- versus -host disease: the Canadian Blood and Marrow Transplant Group randomized 0601 study results
2017
·
Amina Kariminia
, Sabine Ivison
, et al.
·
Haematologica
·
30
PDF
Killer-cell immunoglobulin-like receptor gene profile predicts good molecular response to dasatinib therapy in chronic myeloid leukemia
2012
·
Anna Kreutzman
, Taina Jaatinen
, et al.
·
Experimental Hematology
·
30
PDF
Characteristics and outcomes of acute myelogenous leukemia patients with very late relapse (>5 years)
2007
·
Bruno C. Medeiros
, Mark D. Minden
, et al.
·
Leukemia & lymphoma/Leukemia and lymphoma
·
30
Efficacy and safety following bosutinib dose reduction in patients with Philadelphia chromosome‒positive leukemias
2021
·
Vamsi Kota
, Tim H. Brümmendorf
, et al.
·
Leukemia Research
·
28
Treatment of adults with severe aplastic anemia: Primary therapy with antithymocyte globulin (ATG) and rescue of ATG failures with bone marrow transplantation
1992
·
Michael Crump
, Loree M. Larratt
, et al.
·
The American Journal of Medicine
·
27
Assessment of Early Molecular Response As a Predictor of Long-Term Clinical Outcomes in the Phase 3 BELA Study
2012
·
Tim H Brümmendorf
, Hagop M. Kantarjian
, et al.
·
Blood
·
26
Long‐term patient‐reported outcomes from an open‐label safety and efficacy study of bosutinib in Philadelphia chromosome–positive chronic myeloid leukemia patients resistant or intolerant to prior therapy
2017
·
Hagop M. Kantarjian
, Carla M. Mamolo
, et al.
·
Cancer
·
23
PDF
Effect of Cytomegalovirus Infection on 1‐Year Mortality Rates Among Recipients of Allogeneic Bone Marrow Transplants
1998
·
Atul Humar
, Serena Wood
, et al.
·
Clinical Infectious Diseases
·
20
Show more works
View as search
Works count:
66
Citation count:
3,115
H-index:
23
I10-index:
33
Year
Topic
Type